Ascentage Pharma Group International (HKG:6855)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
45.96
+3.20 (7.48%)
At close: Mar 27, 2026

HKG:6855 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
574.12980.65221.98209.7127.91
Revenue Growth (YoY)
-41.45%341.77%5.85%651.38%124.18%
Cost of Revenue
48.9429.0930.54223.33
Gross Profit
525.18951.57191.44187.7124.58
Selling, General & Admin
599.92383.12376.46328.02191.26
Research & Development
1,137947.25706.97743.1766.49
Operating Expenses
1,7371,3301,0831,071957.75
Operating Income
-1,212-378.8-891.99-883.41-933.17
Interest Expense
-54.07-64.46-96.06-52.79-16.73
Interest & Investment Income
-37.8432.419.737.11
Earnings From Equity Investments
0.31-0.281.08-0.28-
Currency Exchange Gain (Loss)
-6.691.62-2.649.91
Other Non Operating Income (Expenses)
29.94.6320.7849.91139.47
EBT Excluding Unusual Items
-1,236-394.37-932.17-879.48-793.41
Gain (Loss) on Sale of Investments
--0.83-0.7-9.77-20.89
Gain (Loss) on Sale of Assets
--0.0502.07-0.03
Other Unusual Items
-----17.92
Pretax Income
-1,236-395.26-932.86-887.17-832.25
Income Tax Expense
6.9410.43-7.15-4.25-49.83
Earnings From Continuing Operations
-1,243-405.68-925.71-882.92-782.42
Minority Interest in Earnings
0.220.250.08--
Net Income
-1,243-405.43-925.64-882.92-782.42
Net Income to Common
-1,243-405.43-925.64-882.92-782.42
Shares Outstanding (Basic)
356302282264255
Shares Outstanding (Diluted)
356302282264255
Shares Change (YoY)
17.89%7.00%7.07%3.56%17.93%
EPS (Basic)
-3.49-1.34-3.28-3.35-3.07
EPS (Diluted)
-3.49-1.34-3.28-3.35-3.07
Free Cash Flow
--135.65-772.19-857.2-1,040
Free Cash Flow Per Share
--0.45-2.73-3.25-4.08
Gross Margin
91.48%97.03%86.24%89.51%88.08%
Operating Margin
-211.14%-38.63%-401.83%-421.25%-3343.50%
Profit Margin
-216.47%-41.34%-416.98%-421.02%-2803.38%
Free Cash Flow Margin
--13.83%-347.86%-408.75%-3726.60%
EBITDA
-1,132-298.87-812.82-835.99-915.99
EBITDA Margin
-197.22%-30.48%---
D&A For EBITDA
79.9479.9479.1747.4217.18
EBIT
-1,212-378.8-891.99-883.41-933.17
EBIT Margin
-211.14%-38.63%---
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.